PP
GPCR icon

Paloma Partners’s Structure Therapeutics GPCR Stock Holding History

Paloma Partners’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,950
Closed -$435K – 92
2025
Q2 		$435K Buy
+20,950
New +$461K 0.06% 91

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paloma Partners's GPCR Position: Q3 2025 in Review

Paloma Partners sold out of Structure Therapeutics (GPCR) in Q3 2025, closing a stake of 20,950 shares — an estimated $435K sold.

Paloma Partners first reported a position in GPCR in Q2 2025 and held it in 1 quarter. The position peaked at $435K in Q2 2025. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

  • Paloma Partners reported no remaining Structure Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Paloma Partners sold 20,950 Structure Therapeutics shares in Q3 2025, an estimated $435K.
  • Paloma Partners first reported a position in Structure Therapeutics in Q2 2025 and held it in 1 quarter.
  • Paloma Partners's Structure Therapeutics position peaked at $435K in Q2 2025.
  • 156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on Paloma Partners's 13F filing for Q3 2025, filed 14 Nov 2025.